Navigation Links
NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
Date:6/10/2008

SAN MATEO, Calif., June 10 /PRNewswire-FirstCall/ - NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today the publication of Phase 3 data of its lead product candidate, NGX-4010, in the journal Neurology. The paper, titled, "Controlled Trial in High-Concentration Capsaicin Patch for Treatment of Painful HIV Neuropathy," will appear in the June 10, 2008 edition. The topline results from the C107 study were presented in February 2006 by study investigator and lead author, Dr. David Simpson, Professor of Neurology and Director of Clinical Neurophysiology Laboratories and Neuro-AIDS Program at The Mount Sinai Medical Center.

The Phase 3 trial was a randomized, double blind, multicenter, controlled study involving 307 patients with painful HIV-associated distal sensory polyneuropathy (HIV-DSP) receiving a single application of NGX-4010, a high-concentration capsaicin patch. In this trial, the primary endpoint was achieved with a statistically significant reduction in pain over a 12-week period. The NGX-4010 application was well tolerated with the most common side effects being transient application site reactions.

About NeurogesX, Inc.

NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the Company believes offers significant advantages over other pain therapies. NeurogesX' marketing authorization application (MAA) to the European Medicines Agency (EMEA) was accepted for review in September 2007 and NeurogesX plans to file a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) in 2008 for PHN.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the expected benefits of NeurogesX' lead product candidate, NGX-4010. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, NeurogesX' product candidate may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; physician or patient reluctance to use NGX-4010, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in clinical development, obtaining regulatory approval, market acceptance and commercialization of NGX-4010 and the advantages of NGX-4010 over other pain therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

NeurogesX The Ruth Group

Stephen Ghiglieri Investors / Media

(650) 358-3310 Stephanie Carrington / Jason Rando

sghiglieri@neurogesx.com (646) 536-7017 / 7025

scarrington@theruthgroup.com

jrando@theruthgroup.com


'/>"/>
SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
2. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
3. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
4. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
5. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
6. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
7. ASPIRE Independent Review Board Announces 10 Ways to Protect Participants Rights in Clinical Drug Trials and Optimize Results From Research
8. Atrium Medical Corporation Announces First Implant of First-in-Man CINATRA(TM) Voclosporin Coated Coronary Stent
9. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
10. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
11. Anpath Group, Inc. Announces Addition of MRSA and VRE Claims for Its EnviroTru(R) Disinfectant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... April 19, 2017 The Global Effective ... to 2022 report has covered and analysed the potential of ... on market size, shares and growth factors. The report identifies ... and opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major Company ...
(Date:4/19/2017)... 2017  SARES•REGIS Group leased the first of ... Conejo Spectrum Business Park in Thousand ... Inc. , a biopharmaceutical company developing meaningful therapies ... have been underserved by scientific innovation, with an ... autoimmune and infectious disease. Before commencement ...
(Date:4/18/2017)... -- Astute Medical, Inc., developer of biomarkers for better healthcare, ... the 2017 National Kidney Foundation (NKF) Spring Clinical ... 22. Physicians will present data on two biomarkers, ... acute kidney injury (AKI) during the management of patients ... Elevated levels of TIMP-2 and IGFBP-7 have been shown ...
Breaking Medicine Technology:
(Date:4/25/2017)... , ... April 25, 2017 , ... ... have signed an agreement to be the preferred physical therapy provider for Derby ... returning them to Derby City CrossFit as quickly and effectively as possible, ProRehab’s ...
(Date:4/25/2017)... ... April 25, 2017 , ... The doctors at Wall ... who live with dental fear and require sedation to receive dental care. The doctors ... during various procedures, from hygienic cleanings to oral surgery, at their dental office in ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... Back ... neck and back pain with a reputable physician in their area, announces the launch ... protects patient information for patients who are looking for reputable physicians to help them ...
(Date:4/25/2017)... ... April 25, 2017 , ... There is no better place in South ... special report in the May issue of Consumer Reports focused on heart health. ... results achieved during and after coronary bypass and aortic valve replacement procedures. , ...
(Date:4/24/2017)... ... , ... Michael Vick announced his retirement earlier this year from the NFL ... one pick in the 2001 NFL Draft, to the Atlanta Falcons, made four Pro ... career rushing yards by a quarterback (6,109) and the most rushing yards by a ...
Breaking Medicine News(10 mins):